See more : Takeuchi Mfg. Co., Ltd. (6432.T) Income Statement Analysis – Financial Results
Complete financial analysis of Petros Pharmaceuticals, Inc. (PTPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Petros Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- HINDUSTAN APPLIANCES LTD. (HINDAPL.BO) Income Statement Analysis – Financial Results
- HyUnion Holding Co.,Ltd (002537.SZ) Income Statement Analysis – Financial Results
- Yamato Holdings Co., Ltd. (9064.T) Income Statement Analysis – Financial Results
- San Lorenzo Gold Corp. (SNLGF) Income Statement Analysis – Financial Results
- Orient Cement Limited (ORIENTCEM.BO) Income Statement Analysis – Financial Results
Petros Pharmaceuticals, Inc. (PTPI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.petrospharma.com
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.82M | 5.99M | 7.81M | 9.56M | 15.58M | 14.05M |
| Cost of Revenue | 1.63M | 2.29M | 1.60M | 4.05M | 7.43M | 10.48M |
| Gross Profit | 4.19M | 3.70M | 6.21M | 5.51M | 8.15M | 3.57M |
| Gross Profit Ratio | 71.98% | 61.79% | 79.52% | 57.67% | 52.32% | 25.41% |
| Research & Development | 2.41M | 1.74M | 1.79M | 459.64K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -41.15K |
| SG&A | 9.26M | 12.21M | 15.59M | 15.67M | 19.73M | 11.22M |
| Other Expenses | 6.14M | 5.60M | 6.88M | 6.66M | 5.29M | 0.00 |
| Operating Expenses | 17.81M | 19.55M | 24.26M | 22.80M | 25.02M | 11.22M |
| Cost & Expenses | 19.44M | 21.84M | 25.86M | 26.84M | 32.45M | 21.70M |
| Interest Income | 515.31K | 14.19K | 368.66K | 3.05M | 13.84M | 11.86M |
| Interest Expense | 536.14K | 596.02K | 368.66K | 3.05M | 13.84M | 0.00 |
| Depreciation & Amortization | 3.42M | 5.72M | 6.98M | 6.75M | 5.32M | 8.06M |
| EBITDA | -4.21M | -13.73M | -1.64M | -12.21M | -14.00M | 373.58K |
| EBITDA Ratio | -72.34% | -114.20% | -143.00% | -111.11% | -74.32% | 2.95% |
| Operating Income | -13.62M | -15.85M | -18.05M | -17.28M | -16.87M | -7.65M |
| Operating Income Ratio | -233.88% | -264.45% | -231.05% | -180.78% | -108.29% | -54.45% |
| Total Other Income/Expenses | 5.45M | -121.82K | 9.06M | -4.73M | -13.84M | -24.84M |
| Income Before Tax | -8.16M | -20.04M | -8.99M | -22.01M | -33.16M | -32.49M |
| Income Before Tax Ratio | -140.20% | -334.40% | -115.05% | -230.27% | -212.86% | -231.20% |
| Income Tax Expense | 0.00 | 7.00M | 368.66K | -1.43M | -645.87K | -13.37K |
| Net Income | -8.16M | -27.04M | -9.36M | -20.59M | -32.51M | -32.47M |
| Net Income Ratio | -140.20% | -451.22% | -119.77% | -215.35% | -208.71% | -231.10% |
| EPS | -6.35 | -13.06 | -8.59 | -21.21 | -190.46 | -324.73 |
| EPS Diluted | -6.35 | -13.06 | -8.59 | -21.21 | -190.46 | -324.73 |
| Weighted Avg Shares Out | 2.18M | 2.07M | 1.09M | 970.77K | 170.70K | 100.00K |
| Weighted Avg Shares Out (Dil) | 2.18M | 2.07M | 1.09M | 970.77K | 170.70K | 100.00K |
Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces today that Fady Boctor, President and Chief Commercial Officer, will present...
Petros Pharmaceuticals Announces Capital Raise of $15 Million
Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRA NEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the Company"), a pioneer in expanding consumer access to medication through the...
Top Penny Stocks Chart Patterns to Use to Profit
Use these top charts to profit with penny stocks The post Top Penny Stocks Chart Patterns to Use to Profit appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stock Due Diligence: Top Research Techniques
Use these tips for researching penny stocks in 2023 The post Penny Stock Due Diligence: Top Research Techniques appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Buying Energy Penny Stocks? 3 Methods to Use
Investing in energy penny stocks? Here's some top tips The post Buying Energy Penny Stocks?
Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present virtually at the Planet MicroCap Showcase 2022....
3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week
Can these penny stocks climb this coming week? The post 3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks, How To Buy & Strategies for Beginners
Are these strategies on your list for buying penny stocks next month? The post Best Penny Stocks, How To Buy & Strategies for Beginners appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What Are Penny Stocks? What You Need to Know and 3 to Watch
Check these three penny stocks out for your watchlist The post What Are Penny Stocks? What You Need to Know and 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q1 Investor...
Source: https://incomestatements.info
Category: Stock Reports